Benefit of Daflon 500 mg in chronic venous disease-related symptoms

Phlebolymphology

Volumn , Issue 48, 2005, Pages 359-364

  Pitsch, Françoise ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DAFLON;

CLINICAL TRIAL; DRUG EFFICACY; EDEMA; HEALTH CARE QUALITY; HUMAN; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PREVALENCE; QUESTIONNAIRE; REVIEW; SYMPTOM; VEIN DISEASE;

EID: 14644402486     PISSN: 12860107     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Ramelet AA, Kern P, Perrin M, eds. Les varices et télangiectasies. Paris: Massen; 2003:7-16.
2. Porter JM, Moneta GL. International Consensus Committee on chronic venous disease. Reporting standards in venous disease: an update. J Vasc Surg. 1995;21:635-645.
3. Bradbury A, Evans C, Allan P, Ruckley CV, Fowkes FGR. What are the symptoms of varicose veins? Edinburgh vein study cross sectional population survey. BMJ. 1999;318:353-356.
4. Bradbury A, Evans CJ, Allan P, Lee AJ, Ruckley CV, Fowkes FGR. The relationship between lower limb symptoms and superficial and deep venous reflux on duplex ultrasonography: the Edinburgh Vein Study. J Vasc Surg. 2000;32:921-931.
5. Labropoulos N. Inflammation parallels severity of chronic venous insufficiency. Phlebology. 2003;18:78-82.
6. Pannier-Fischer F, Rabe E. Epidemiology of chronic venous diseases. Hautarzt. 2003;54:1037-1044.
7. Jawien A, Grzela T, Ochwat A. Prevalence of chronic venous insufficiency in men and women in Poland: multicentre cross-sectional study in 40,095 patients. Phlebology. 2003;18:110-122.
8. Labropoulos N. Hemodynamic changes according to the CEAP classification. Phlebolymphology. 2003;40:130-136.
9. Masuda EM, Kisner RL, Eklof B, Yang D. Practical application of the CEAP classification. In: Ballard JL, Bergan JJ, eds. Chronic Venous Insufficiency, Diagnosis and Treament. London: Springer-Verlag London Limited; 2000:41-49.
10. Scuderi A, Raskin B, Assal FA, Scuderi P, et al. The incidence of venous disease in Brazil based on the CEAP classification. An epidemiological study. Int Angiol. 2002;21:316-321.
11. Carpentier PH, Cornu-Thénard A, Uhl JF, Partsch H, Antignani PL and the European working group on the clinical characterisation of venous disorders. Appraisal of the information content of the C classes of CEAP clinical classification of chronic venous disorders: a multicenter evaluation of 872 patients. J Vasc Surg. 2003;37:827-833.
12. Boisseau MR. Pharmacologie des médicaments veinotoniques : données actuelles sur leur mode d'action et les cibles thérapeutiques. Angéiologie. 2000;52:71-77.
13. Clarke GH, Vasdekis SN, Hobbs JT, Nicolaides AN. Venous wall function in the pathogenesis of varicose veins. Surgery. 1992;111:402-408.
14. Boisseau M, Freyburger G, Busquet M, et al. Hemorheological disturbances in venous insufficiency after induced stasis. Clin Hemorheol. 1989;9:161-163.
15. Le Devehat C, Boisseau MR, Vimeux M, et al. Hemorheological factors in the pathophysiology of venous disease. Clin Hemorheol. 1989;9:861-870.
16. Garde C, Perrin M, Chleir F, Henriet JP et al. First meeting of review and consensus on venoactive agents on the symptoms of chronic venous disease. (In French). Phlébologie. 2003;56:103-109.
17. Agence Nationale d'Accréditation et d'Evaluation de la Santé. Evaluation et suivi de la douleur chronique chez l'adulte, en médecine ambulatoire www.anaes.fr
18. Rutherford RB, Padberg FT Jr, Comerota AJ, Kistner RL, Meissner MH, Moneta GL. Venous severity scoring: an adjunct to venous outcome assessment. J Vasc Surg. 2000;31:1307-1312.
19. Lamping DL, Schroter S, Kurz X, Kahn S, Abenhaim L. Evaluation of outcomes in chronic venous disorders of the leg: development of a scientifically rigorous, patient-reported measure of symptoms and quality of life. J Vasc Surg. 2003;37:410-419.
20. Chassignolle J-F, Amiel M, Lanfranchi G, et al. Activité thérapeutique de Daflon 500 mg dans l'insuffisance veineuse fonctionnelle. J Int Med. 1987;99(Suppl) 32-37.
21. Gilly R, Pillion G, Frileux C. Evaluation of a new venoactive micronized flavonoid fraction (S 5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: a double-blind, placebo-controlled study. Phlebology. 1994;9:67-70.
22. Jantet G. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of life improvEment with micronized Flavonoids. Angiology. 2002;53:245-256.
23. Guillot B, Guilhou JJ, de Champvallins M, et al. A long term treatment with a venotropic drug: results on efficacy and safety of Daflon 500 mg in chronic venous insufficiency. Int Angiol. 1989;8(4 Suppl):67-71.
24. Italian College of Phlebology. Guidelines for the diagnosis and treatment of chronic venous insufficiency. Int Angiol. 2001:20(2 Suppl 2):1-37.
25. Coleridge Smith PD. The drug treatment of chronic venous insufficiency and venous ulceration. In: Gloviczki P, Yao JST, eds. Handbook of Venous Disorders: Guidelines of the American Venous Forum. 2nd ed. London: Arnold; 2001:309-321.
26. Lyseng-Williamson KA, Perry CM. Micronised purified flavonoid fraction. A review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids. Drugs. 2003;63:71-100.